European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading

MT Newswires Live09-12

European equities traded in the US as American depositary receipts were treading water late Thursday morning, nudging 0.1% lower to 1,424.33 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by internet browser company Opera (OPRA) and internet ad agency Criteo (CRTO), which rose 2.8% and 2%, respectively. They were followed by Sequans Communications S.A. (SQNS) and biopharmaceutical company Cellectis (CLLS), which were up 1.7% and 1.3%, respectively.

The decliners from continental Europe were led by furniture maker Natuzzi (NTZ) and biotech firm Evaxion Biotech (EVAX), which fell 6% and 3% respectively. They were followed by biotech firm BioNTech (BNTX) and biopharmaceutical company Grifols (GRFS), which were up 2.7% and 2.3%, respectively.

From the UK and Ireland, the gainers were led by biopharmaceutical company TC Biopharm (TCBP) and cruise line operator Carnival (CUK), which advanced 16% and 3.7%, respectively. They were followed by alcoholic beverage company Diageo (DEO) and biopharmaceutical company Bicycle Therapeutics (BCYC), which increased 2.6% each.

The decliners from the UK and Ireland were led by biotech firm Autolus Therapeutics (AUTL) and biopharmaceutical company Amarin (AMRN), which fell 2.8% and 2%, respectively. They were followed by biopharmaceutical company Mereo BioPharma Group (MREO) and pharmaceutical company AstraZeneca (AZN), which were down 1.7% each.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment